Key Laboratory of Receptors-Mediated Gene Regulation, School of Medicine, Henan University, Kaifeng, China.
Kaifeng Key Laboratory of Radiation Oncology, Kaifeng Cancer Hospital, Kaifeng, China.
Front Immunol. 2023 Jul 27;14:1221418. doi: 10.3389/fimmu.2023.1221418. eCollection 2023.
Primary liver cancer is characterized by closely related with chronic liver inflammation, thereby reversing hypoxic immunosuppressive microenvironment of tumor cell growth by immunotherapy drug is a potentially effective strategy. Camrelizumab is an anti-PD-1 antibody being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. We reported a case of an adult critical Chinese patient with primary hepatocellular carcinoma and lung metastasis completely responding to Camrelizumab, most of the lesions were stable and no new lesions occurred after 1-year treatment, which provides us to reconsider the therapeutic effect of Camrelizumab on such patients. Camrelizumab had a safety profile for the patient in our case report, except for the occurrence of RCCEP. This case provides the evidence of the effective antitumor activity and manageable toxicities of Camrelizumab for patients with advanced hepatocellular carcinoma, which was the first application as far as we know.
原发性肝癌的特征是与慢性肝炎症密切相关，因此通过免疫治疗药物逆转肿瘤细胞生长的低氧免疫抑制微环境是一种潜在有效的策略。卡瑞利珠单抗是江苏恒瑞医药股份有限公司开发的一种抗 PD-1 抗体。我们报告了一例成人原发性肝癌伴肺转移的危重症中国患者，用卡瑞利珠单抗治疗后完全缓解，大多数病变稳定，治疗 1 年后无新病变发生，这使我们重新考虑卡瑞利珠单抗对这类患者的治疗效果。在我们的病例报告中，卡瑞利珠单抗对该患者的安全性特征除了发生 RCCEP 外。该病例为晚期肝细胞癌患者提供了卡瑞利珠单抗有效抗肿瘤活性和可管理毒性的证据，据我们所知，这是首次应用。
